Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Amortization - Intangibles (2016 - 2025)

Vanda Pharmaceuticals' Amortization - Intangibles history spans 16 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Amortization - Intangibles changed 0.0% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $7.0 million, down 4.69%, while the annual FY2025 figure was $7.0 million, 3.66% down from the prior year.
  • Amortization - Intangibles for Q4 2025 was $1.8 million at Vanda Pharmaceuticals, roughly flat from $1.8 million in the prior quarter.
  • Across five years, Amortization - Intangibles topped out at $2.0 million in Q1 2024 and bottomed at $358000.0 in Q4 2022.
  • The 5-year median for Amortization - Intangibles is $400000.0 (2022), against an average of $976150.0.
  • The largest annual shift saw Amortization - Intangibles skyrocketed 400.0% in 2024 before it dropped 12.4% in 2025.
  • A 5-year view of Amortization - Intangibles shows it stood at $369000.0 in 2021, then fell by 2.98% to $358000.0 in 2022, then skyrocketed by 176.54% to $990000.0 in 2023, then skyrocketed by 76.97% to $1.8 million in 2024, then changed by 0.0% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Amortization - Intangibles are $1.8 million (Q4 2025), $1.8 million (Q3 2025), and $1.8 million (Q2 2025).